Zentalis Pharmaceuticals, Inc. (ZNTL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Zentalis Pharmaceuticals, Inc. (ZNTL) closed at USD 2.32 on 2026-10-14, a change of +35.7 % over the past year, with a market capitalization of USD 219.79M.

Zentalis Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Zentalis Pharmaceuticals, Inc. key figures

Previous close

USD 2.32 (2026-10-14)

1-year change

+35.7 %

Market cap

USD 219.79M

Enterprise value

USD 23.63M

P/E ratio (trailing)

-1.23

P/E ratio (forward)

-1.26

EPS (trailing)

-1.82

EPS (forward)

-1.78

PEG ratio

n/a

Price to book

1.12

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.11

Employees

106

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Zentalis Pharmaceuticals, Inc. and compare it with other stocks.